The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma
have increased the complexity of patient management. A dynamic adaptation of the …

Background & Aims Proton beam radiotherapy (PBT) has recently been applied to treat
hepatocellular carcinoma (HCC); however, there is no randomized controlled trial-based …

Purpose To compare the efficacy and safety of combined treatment with lenvatinib and
transarterial chemoembolization (TACE) versus TACE only in patients with unresectable …

Abstract The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on
the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) …

Background & Aims Biannual ultrasound has poor sensitivity for hepatocellular carcinoma
(HCC) screening. MRI is accurate for the detection of HCC, but a complete MRI is not …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma …